Exploring the next “phage” of treating non-tuberculous mycobacterial infections
Infection · 2026-10 · 54 (5) · 2161-2175
DOI: 10.1007/s15010-026-02818-7 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Infection, online erschienen am 01.06.2026. Verfasst von Max Kevane-Campbell und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department II of Internal Medicine, Infectious Diseases, Goethe University Frankfurt, University Hospital, Frankfurt am Main, Germany. kevane-campbel…. Hauptthemen laut MEDLINE: Phage Therapy, Mycobacterium Infections, Nontuberculous, Mycobacteriophages, Nontuberculous Mycobacteria. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 119 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Johann Wolfgang Goethe-Universität, Frankfurt am Main.
Abstract (Originalsprache)
Non-tuberculous mycobacteria (NTM) can present a serious clinical threat due to their resistance to conventional antibiotics and their ability to cause persistent infections. As antimicrobial resistance (AMR) represents one of the most significant global health threats, mycobacteriophages (MPs)—viruses that specifically target mycobacterial species—are emerging as a promising therapeutic addition or alternative. This review explores the biological characteristics, therapeutic mechanisms, and clinical potential of MPs, with a primary focus on their use against NTM infections. Based on data from in vitro studies, animal models, and human compassionate-use cases, we highlight the mycobactericidal efficacy of MPs as well as their potential to complement antibiotic treatment regimens. However, there are key challenges that need to be addressed to implement MPs as therapeutics—such as limited host range, immune response interference, MP resistance, and intracellular delivery barriers. The implementation of MP banks, standardized regulatory protocols, and approved clinical trials is highly essential for MP therapy to transition smoothly into the healthcare sectors. By carrying out coordinated scientific, regulatory, and clinical efforts, MP-based therapy holds a promising potential in combating antibiotic-resistant NTM infections.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department II of Internal Medicine, Infectious Diseases, Goethe University Frankfurt, University Hospital, Frankfurt am Main, Germany. kevane-campbell@med.uni-frankfurt.de.
- Mycobacterial Infection Research Unit (MIRU), Goethe University Frankfurt, Frankfurt am Main, Germany. kevane-campbell@med.uni-frankfurt.de.
- Institute for Medical Microbiology and Infection Control, Goethe University Frankfurt, University Hospital, Frankfurt am Main, Germany. kevane-campbell@med.uni-frankfurt.de.
- Department II of Internal Medicine, Infectious Diseases, Goethe University Frankfurt, University Hospital, Frankfurt am Main, Germany.
- Mycobacterial Infection Research Unit (MIRU), Goethe University Frankfurt, Frankfurt am Main, Germany.
- Institute for Medical Microbiology and Infection Control, Goethe University Frankfurt, University Hospital, Frankfurt am Main, Germany.
Förderung
- Johann Wolfgang Goethe-Universität, Frankfurt am Main
Zitieren
APA
Kevane-Campbell, M., Idris, R., Würstle, S., Lieberknecht, S., Vehreschild, M. J. G. T., Wichelhaus, T. A., & Wetzstein, N. (2026). Exploring the next “phage” of treating non-tuberculous mycobacterial infections. Infection, 54(5), 2161-2175. https://doi.org/10.1007/s15010-026-02818-7
Vancouver
Kevane-Campbell M, Idris R, Würstle S, Lieberknecht S, Vehreschild MJGT, Wichelhaus TA, et al. Exploring the next “phage” of treating non-tuberculous mycobacterial infections. Infection. 2026;54(5):2161-2175. doi:10.1007/s15010-026-02818-7
BibTeX
@article{KevaneCampbell2026,
author = {Kevane-Campbell, Max and Idris, Raja and Würstle, Silvia and Lieberknecht, Simone and Vehreschild, Maria J G T and Wichelhaus, Thomas A and Wetzstein, Nils},
title = {Exploring the next “phage” of treating non-tuberculous mycobacterial infections},
journal = {Infection},
year = {2026},
volume = {54},
number = {5},
pages = {2161--2175},
doi = {10.1007/s15010-026-02818-7}
}
EUVIMED